Study of BMS-986012 in Subjects With Small Cell Lung Caner

A Phase 1 Study of the Safety and Tolerability of BMS-986012 in Subjects With Small Cell Lung Cancer

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223369

Enrollment

Registered

2016-11-08

Start date

2016-11-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Interventions

investigational material(s) Generic name etc : BMS-986012, Cisplatin, Etoposide INN of investigational material : Cisplatin, Etoposide Therapeutic category code : 42- Antineoplastic agents Dosage and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histological or cytological confirmed small cell lung cancer (SCLC) Eastern Cooperative Oncology Group Performance Status 0-1 at least one measurable lesion that is not amenable to resection. Adequate organ function

Exclusion criteria

Exclusion criteria: Symptomatic central nervous system (CNS) metastases Greater than or equal to Grade 2 peripheral neuropathy Uncontrolled or significant cardiac disease Active or chronic infection with Human Immunodeficiency Virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV)

Design outcomes

Primary

Measure	Time frame
Safety and Tolerability Number of participants with adverse events (AEs) Number of participants with serious adverse events (SAEs ) Number of Discontinuations due to AEs Number of Deaths due to AEs Number of participants with laboratory toxicity grade shift from baseline	—

Secondary

Measure	Time frame
Pharmacokinetics (PK) Immunogenicity Efficacy Following PK Parameters: Cmax, Tmax, AUC(0-T), Ctau, AUC(TAU) Anti-drug antibodies (ADA) Best overall response (BOR) and duration of response (DOR)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026